Cargando…

Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome

In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prince, H. Miles, Martin, Ann G., Olsen, Elise A., Fivenson, David P., Duvic, Madeleine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523809/ https://www.ncbi.nlm.nih.gov/pubmed/22738414 http://dx.doi.org/10.3109/10428194.2012.706286

Ejemplares similares

Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
por: Kaminetzky, David, et al.
Publicado: (2008)

Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
por: Lewis, Daniel J., et al.
Publicado: (2017)

Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome
por: Lee, Hyewon
Publicado: (2023)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

TOX Expression in Mycosis Fungoides and Sezary Syndrome
por: Pileri, Alessandro, et al.
Publicado: (2022)

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
por: Lansigan, Frederick, et al.
Publicado: (2010)

The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome
por: Liu, Zhaorui, et al.
Publicado: (2021)

Mycosis Fungoides and Sézary Syndrome: Microenvironment and Cancer Progression
por: Dobos, Gabor, et al.
Publicado: (2023)

Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
por: Cervigón-González, Iván, et al.
Publicado: (2011)

Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
por: Amagai, Mayuko, et al.
Publicado: (2022)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
por: Lechowicz, Mary Jo, et al.
Publicado: (2014)

Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
por: Vural, Seçil, et al.
Publicado: (2018)

Acute progression of the leukemic phase in mycosis fungoides and Sézary syndrome
por: Maredia, Hasina, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario()()
por: Sanches, José Antonio, et al.
Publicado: (2021)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
por: Fuentes, Alejandra C., et al.
Publicado: (2015)

Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update()
por: Yamashita, Thamy, et al.
Publicado: (2012)

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
por: Oka, Tomonori, et al.
Publicado: (2019)

A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome
por: Egger, Andjela, et al.
Publicado: (2020)

Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020
por: Ottevanger, R., et al.
Publicado: (2021)

The incidences of other primary cancers in patients with mycosis fungoides and Sézary syndrome
por: Błażewicz, Izabela, et al.
Publicado: (2021)

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
por: Telang, Sucheta, et al.
Publicado: (2011)

Expression of Thymidine Phosphorylase in Lymph Nodes Involved with Mycosis Fungoides and Sézary Syndrome
por: Nie, Xingcao, et al.
Publicado: (2011)

The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications
por: Pileri, Alessandro, et al.
Publicado: (2021)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management
por: Miyashiro, Denis, et al.
Publicado: (2023)

Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome
por: ALENEZI, Fawaz, et al.
Publicado: (2021)

Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome
por: Tran, Jessica, et al.
Publicado: (2020)

Strategies to Optimize Adherence in Patients with Mycosis Fungoides
por: Chan, Warren H., et al.
Publicado: (2021)

The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist’s Point of View
por: Giordano, Antonio, et al.
Publicado: (2022)

Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
por: García-Díaz, Nuria, et al.
Publicado: (2021)

Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature
por: Ottevanger, R., et al.
Publicado: (2021)

Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

Itchy Skin: A Challenging Differential Diagnosis Between Mycosis Fungoides and Sézary Syndrome
por: Abreu Rocha, Cláudia, et al.
Publicado: (2023)

Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides
por: Campbell, Belinda A., et al.
Publicado: (2019)

Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome
por: Fong, Sophia, et al.
Publicado: (2020)

Photodynamic Therapy with the Silicon Phthalocyanine Pc 4 Induces Apoptosis in Mycosis Fungoides and Sezary Syndrome
por: Lam, Minh, et al.
Publicado: (2010)

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_04sb6h1g2k18gk36atueu61bg5